GlycoMimetics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 51
- Market Cap
- $11.6M
- Website
- http://www.glycomimetics.com
Clinical Trials
27
Active:7
Completed:15
Trial Phases
3 Phases
Phase 1:22
Phase 2:1
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
Phase 1
22 (81.5%)Phase 3
4 (14.8%)Phase 2
1 (3.7%)A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
Phase 1
Terminated
- Conditions
- HR+ Metastatic Breast CancerBreast Cancer MetastaticBreast Cancer
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 4
- Registration Number
- NCT04197999
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 388
- Registration Number
- NCT03616470
- Locations
- 🇺🇸
UC San Diego Moore Cancer Center, La Jolla, California, United States
🇺🇸University of California, Los Angeles - UCLA, Los Angeles, California, United States
🇺🇸University of California Irvine, Orange, California, United States
A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV)
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 5
- Registration Number
- NCT03606447
- Locations
- 🇬🇧
Quotient Sciences Limited, Ruddington, Nottingham, United Kingdom
A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 16
- Registration Number
- NCT02998099
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 58
- Registration Number
- NCT02931214
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found